Frost & Sullivan Independent Equity Research

Oramed Pharmaceuticals Inc.: Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed’s clinical progress meets our expectations, stock target price remains at NIS 53.2.

Company: Oramed Pharmaceuticals Inc.

Sector: Pharmaceuticals

Report type: Update for the quarter ending 31 May 2018

Published on: 24 July, 2018

View Fullscreen

Download full report

Oramed research articles:

Update for the quarter ending 31 May 2018 ·

Oramed Pharmaceuticals Inc.: Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed’s clinical progress meets our expectations, stock target price remains at NIS 53.2.

Initiation of Coverage ·

Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2

All articles loaded

No more articles to load

INDEPENDENT EQUITY RESEARCH

Tel: +972(0)9.950.2888
Email: equity.research@frost.com

Contact us

Copyright © 2020 Frost & Sullivan. All Rights Reserved. Privacy Policy.

Accessibility by WAH